Navigation Links
BioRelix and Dalton Medicinal Chemistry Sign Research Agreement to Capitalize on RiboSwitch Technology
Date:11/13/2007

NEW HAVEN, CT, and TORONTO, Nov. 13 /PRNewswire/ - BioRelix, pioneers in the discovery and development of RiboSwitch based therapeutic agents and Dalton Medicinal Chemistry, have jointly announced a research collaboration to discover new therapeutics.

Dalton Medicinal Chemistry will utilize their proprietary insights to design and synthesize several novel classes of compounds against selected RiboSwitch targets. BioRelix will advance these compounds using their cutting edge battery of biological assays and thorough knowledge of RiboSwitch drug discovery and development.

Brian Dixon, BioRelix CEO commented: "We are pleased to have the opportunity to work with the creative team at Dalton Medicinal Chemistry in the discovery of new entities for treating infectious diseases. Their expertise, coupled with our proprietary and leading position in RiboSwitch technology will lead to important new medicines."

Judd Berman, Co-founder of Dalton Medicinal Chemistry, said: "We are delighted to have this opportunity to work with BioRelix in the discovery of much needed new anti-infective agents. The team at BioRelix has clearly established an exceptionally innovative approach to anti-infectives."

About BioRelix

BioRelix Pharmaceuticals, Inc. is a drug discovery and development company focused on identifying new anti-infective drug treatments. BioRelix is building a portfolio of anti-infective products based on novel patented RNA targets, termed RiboSwitches, which were identified in the laboratory of BioRelix co-founder, Ronald Breaker Ph.D., Howard Hughes Investigator and Henry Ford II Professor at Yale University. BioRelix investors include CHL Medical Partners, New Leaf Venture Partners, Aisling Capital, Novartis Venture Fund, Elm Street Ventures and Alexandria Real Estate Equities.

About Dalton Pharma Services

Dalton Chemical Laboratories Inc. o/a Dalton Pharma Services is a Health Canada approved contract pharmaceutical manufacturer that supplies chemistry and analytical services to the biotechnology and pharmaceutical industries in the areas of chemistry, medicinal chemistry and fine chemical manufacture. Dalton provides cGMP manufacturing and sterile filling services to its customers at any stage of the regulatory process (Phase I, II, III or commercial). In its state of the art cGMP facilities, Dalton produces active pharmaceutical ingredients at the gram or kilogram scale. Dalton conducts sterile fills to produce batches of finished drug product in vials or syringes, either aseptically filled or terminally sterilized, under fully validated conditions. In addition, Dalton's analytical chemistry laboratory offers method development, validation and ICH stability programs to its clients.


'/>"/>
SOURCE Dalton Pharma Services
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Dalton Medicinal Chemistry Partners Achieves Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
2. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
3. Sequella Lead Drug Compound SQ109 Receives Orphan Drug Status From the US FDA and Orphan Medicinal Product Designation From the European Medicines Agency for the Treatment of Tuberculosis
4. Argonne scientist to give the plenary talk at Royal Society of Chemistry meeting on nanoalloys
5. Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
6. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
7. MedAssets Supply Chain Systems Selects Siemens Medical Solutions Diagnostics for Chemistry, Automation and Immunoassay Solutions
8. GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics Based on Boron Chemistry
9. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
10. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
11. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... Today, researchers can fast-track sample ... acid, and/or other biomarkers or SNPs of interest) using one, easy-to-collect saliva sample. ... the relationship between insulin and other relevant biomarkers can be extensively studied through ...
(Date:2/23/2017)... ANGELES , Feb. 23, 2017  Capricor Therapeutics, Inc. ... and other medical conditions, today announced that Linda Marbán, Ph.D, ... two upcoming investor conferences: Cowen and ... at 10:00 am ET Boston, MA ... 2017 at 9:00 am PT (12:00 pm ET) ...
(Date:2/23/2017)... and SAN FRANCISCO , Feb. 23, ... medicine company, and Beyond Type 1, a not-for-profit advocacy ... diabetes, today announced a grant from Beyond Type 1 ... for type 1 and other insulin-requiring diabetes.  ... developing innovative stem cell-derived cell replacement therapies with a ...
(Date:2/22/2017)... 22, 2017  Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet ... innovative biopharmaceutical products for companion animals, will host a live ... ET to discuss financial results from the fourth quarter and ... participants and investors may access the audio webcast ... ...
Breaking Biology Technology:
(Date:1/26/2017)... , Jan. 26, 2017  Acuity Market Intelligence ... Biometrics and Digital Identity".  Acuity characterizes 2017 as ... when increased adoption reflects a new understanding of ... "Biometrics and digital identity are often perceived ... Maxine Most , Principal of Acuity Market intelligence. ...
(Date:1/24/2017)...  It sounds simple and harmless—an electronic sensor ... signs and alerts parents on their smart phones ... drops. But pediatric experts argue that such devices ... evidence of medical benefits, especially to healthy babies. ... parents of healthy babies, promising peace of mind ...
(Date:1/19/2017)... , January 19, 2017 According to a new ... and Forecast, 2014 - 2022," the global biometric sensor market is expected to ... to 2022. In 2015, Asia-Pacific dominated the global market ... private sectors. Continue Reading ... ...
Breaking Biology News(10 mins):